1. Introduction {#s0005}
===============

In December 2019, the first outbreak of respiratory contagion owing an uncharted etiology was reported in Wuhan city of China. The World Health Organisation (WHO) used the term '*novel corona virus 2019*' on 29th December 2019 for the outbreak that affected humans in Wuhan, China, which currently is being referred as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as proposed by Coronavirus Study Group (CSG) of the International Committee on 11th February 2020 ([@bb0170]). Further, the official name of the disease caused by SARS-CoV-2 has been termed as coronavirus disease (COVID-19) by WHO ([@bb0545]; [@bb0590]; [@bb0595]; [@bb0635]; [@bb0640]). The genomic characterization revealed close relation of COVID-19 virus with the two bat coronaviruses (SARS-CoV and pangolin coronaviruses) and further the linkage of most of the cases to the Huanan Seafood Wholesale Market, indicating its zoonotic origin ([@bb0320]; [@bb0355]; [@bb0135]; [@bb0580]). The virus is reported to belong to the group of β -- coronavirus ([@bb0545]). The virus is named as coronavirus due to its particular shape resembling a crown with projected spikes made of protein. The coronavirus comprises of a capsid with single-stranded ribonucleic acid (ssRNA), which is allied with a nucleoprotein in matrix protein ([@bb0510]). Like other SARS virus, the SARS-CoV-2 has three types of hosts (i.e. natural, intermediate, and final), leading to a great amount of difficulty in its prevention and treatment ([@bb0545]). SARS-CoV-2 has caused much greater pandemics than severe acute respiratory syndrome (SARS) in 2002--2004 and Middle East Respiratory Syndrome-related Coronavirus (MERS) in 2012.

As reported by [@bb0550], the COVID-19 outbreak range is rapid and more extensive than SARS. According to WHO report published on 29th February, as of 12th February 2020, a total number of infected cases were 79,394 cases and 2838 deaths ([@bb0550]) and one month after, on 11th March 2020, COVID-19 was declared as a global pandemic owing to unprecedented global escalation in the affected people, and gravity of likely repercussions. An exponential curve has already been shaped up by mid of the March 2020, for both total infected people and deaths. By the time the revision of the present work is being submitted i.e. till 29th April 2020, WHO reports 3,018,952 worldwide confirmed cases of COVID-19 infection with a death count of 207,973 around the globe, derailing every business sectors, institutions, life, public health, and the world economy ([@bb0365]; [@bb0545]; [@bb0550]; [@bb0555]; [@bb0560]).

The present review work provides a comprehensive platform to understand about COVID-19 from the point view of its: i) virology and genome, ii) Epidemiology, iii) Symptoms and Prognosis, iv) Pathogenesis and Diagnosis, v) Transmission routes, vi) Effect of environmental factors, and vii) existing treatment strategies/management for COVID-19. The present work intend to not only help the scientific community by enlisting probable future research directions pertaining to COVID-19, but will also act as a general awareness guide for the public and policymakers.

2. Virology and genome of SARS-CoV-2 {#s0010}
====================================

[Fig. 1](#f0005){ref-type="fig"}(a) demonstrates the naming of coronavirus with respect to virus taxonomy and diseases caused in a timeline fashioned, and [Fig. 1](#f0005){ref-type="fig"}(b) provides a descriptive phylogenetic tree of SARS-like coronaviruses (CoV) i.e. SARS-CoV, MERS-CoV, and SARSCoV-2. According to [@bb0270] genome of SARS-CoV-2 has ten open reading frameworks (ORFs) that are similar to other CoV. [Fig. 1](#f0005){ref-type="fig"}(c) illustrates that at 1/3rd of the genome, the ORFs encode four main structural proteins: spike (S), envelope (E), nucleocapsid (N), and membrane (M) protein in SARS-CoV-2, SARS-CoV and MERS-CoV. SARS-CoV-2 belongs to a particular class of viruses with enveloped structure, containing single-stranded RNA ([@bb0510]; [@bb0465]) and has a base pair (bp) of about 26--32 kilobase (kb) ([@bb0465]) of diameter 80--120 nm ([@bb0545]). As reported by the studies of [@bb0075], [@bb0360] and [@bb0465], there are four identified genera of coronavirus i.e. α, β, γ, δ. It was β-CoV that was isolated and identified in the patients of Wuhan city (China) at the onset of outbreak. β-CoV has 88% resemblance with bat-SL-CoVZC45 and bat-SL-CoVZXC21 ([@bb0305]), and about 79% of the genomic resemblance of SARS-CoV-2, is reported with SARS-like bat COV-MG772933 ([@bb0590]). The International Committee on Taxonomy of Viruses (ICTV) ([@bb0100]) declared isolated β-CoV as "SARS-CoV-2 owing to the genetic similarity of the coronavirus to the virus of SARS outbreak of 2003" ([@bb0170]; [@bb0465]).Fig. 1(a) Naming of coronavirus with respect to taxonomy and disease caused \[Modified from [@bb0155] (Nature Microbiology)\]; (b) Phylogenetic tree of SARS-like coronaviruses and (c) Open reading frame (ORF) SARS-like coronaviruses \[Figure adopted from [@bb0270] (Pharmaceutical Analysis)\].Fig. 1

3. COVID-19 outspread: infection and morbidity {#s0015}
==============================================

On 9th January 2020, Wuhan witnessed the first confirmed death due to COVID-19 ([@bb0490]). The Philippines on 1st February reported first death outside China province ([@bb0385]), and on 14th February, France reported first death outside Asia ([@bb0485]). COVID-19 spread has been rapid and random comprising dozens of deaths in Iran, South Korea, and Italy by 28th February ([@bb0495]). Around 40 countries over all the continents, except the Antarctica, had reported deaths by 13th March 2020 ([@bb0165]). [Fig. 2](#f0010){ref-type="fig"} represents the total and daily new confirmed cases ([Fig. 2](#f0010){ref-type="fig"}a) and deaths ([Fig. 2](#f0010){ref-type="fig"}b) worldwide till 29th April 2020, by when the daily new cases are \~70,000, and daily reported new deaths are \>5000. Since the start of this pandemic till 29th April 2020, WHO reports 3,018,952 confirmed cases worldwide with a death count of 207,973 ([@bb0570]). However, actual case count is likely to be much higher than the reported count owing to lack of testing, in general; and especially for the asymptomatic patients ([@bb0405]). Likewise, the actual death count is much higher because as per the standard official protocols, the death accounted in the report is only of people who were tested positive for COVID-19 ([@bb0400]).On the other hand, as of 29th April 2020, total of 991,999 cases have been recovered from COVID-19 across the world as per the data collected by John Hopkin University, USA ([@bb0200]).Fig. 2Cumulative variation in total and daily new COVID-19 a) Cases, and b) deaths in the world since December 31st and April, 30th 2020. \[Data Source: [ourworldindata.org](http://ourworldindata.org){#ir0005}\].Fig. 2

[Fig. 3](#f0015){ref-type="fig"}(a) shows the spread of total confirmed cases of COVID-19 in the top 25 countries, in terms of % active cases (current laboratory confirmed cases), % deaths, and % recovered cases, and in comparison to the world cases ([Fig. 3](#f0015){ref-type="fig"}(b)). Supplementary Table 1 reports countries and territories with laboratory-confirmed COVID-19 cases and deaths as per the [@bb0570]. Till 29th April 2020, the USA is the most infected country in terms of confirmed cases (983,457) followed by Spain (210,773), Italy (201,505), United Kingdom (161,149), Germany (157,641), France (125,464), Turkey (114,653), Russia (99,399), Iran (92,584), and China (84,369) ([@bb0570]). While the order of top ten countries changes for the reported death count where the USA (50,492) remained at the first place but the Italy (27,359) supersedes Spain (23,822), and rest countries follows the order of France (23,627) \> United Kingdom (21,678) \> Germany (6115) \> Iran (5877) \> China (4643) \> Turkey (2992) \> Russia (972) ([@bb0570]). However the most interesting thing is ratio of reported death versus reported case in these top ten countries that varied between 18.8% to 1.0% with an order of France (18.8%) \> Italy (13.6%) \> UK (13.5%) \> Spain (11.3%) \> Iran (6.3%) \> China (5.5%) \> USA (5.1%) \> Germany (3.9%) \> Turkey (2.6%) \> Russia (1.0%). Such a huge variation in the mortality rate seems to be governed by various factors like population characteristics (sex, age, and overall health), time since the initial outbreak, healthcare system quality, the volume of testing and treatment options ([@bb0420]). In general, countries (i.e. China, Iran, Switzerland, Germany, Mexico, Israel, Spain and Ireland) with early outbreak of COVID-19 are showing considerable recovery rate; with china being on the top with \~95% of the recovery from the infection. It looks like that fatality rate is considerably high (\>10%) in European countries like Italy, Spain, UK, Netherlands, Belgium, France, Sweden and Mexico. The Supplementary Table 1 reports Countries and territories with laboratory-confirmed COVID-19 cases and deaths ([@bb0570]). Overall, there seem to exist a globally good correlation between daily reported active cases and total active cases around the world ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Distribution of COVID-19 Cases among active, recovered and deaths in a) the world; and b) top 25 infected countries (By 30th April 2020) \[Data Source: [worldometers.info](http://worldometers.info){#ir0010}\].Fig. 3

4. Swinging symptoms of COVID-19 {#s0020}
================================

COVID-19 infected patients exhibit mostly symptoms like fever, fatigue, headache, cough, difficulty in breathing, and sore throat ([@bb0160]; [@bb0190]). Based on 1099 samples of the confirmed cases of COVID-19, till 29th January 2020, the common clinical manifestations were in order of high temperature (89%) \> cough (68%) \> tiredness (38%) \> sputum (33%) \> breath shortening (19%) \> sore throat (14%) \> headache (14%) \> vomiting (5%) \> diarrhea (4%). These manifestations show consistency with previous analysis of Hubei province, China ([@bb0545]; [@bb0550]; [@bb0555]; [@bb0560]; [@bb0190]; [@bb0080]). Thus, the dominant symptoms of COVID-19 are fever and cold; and rare symptoms are respiratory and gastrointestinal. Such symptomatic condition implies that SARS-COV-2 exhibits different viral tropism than other influenza causing viruses like MERS-CoV ([@bb0025]), and SARS-CoV ([@bb0255]; [@bb0540]). The earliest screening may be carried out with the help of neutrophil to lymphocyte ratio (NLR) ([@bb0375]), as infection instantly leads to the reduction of lymphocytes which causes an increase in NLR ([@bb0160]; [@bb0285]; [@bb0290]).

Overall, WHO defines COVID-19 patient as: i) An individual with acute respiratory illness like fever and/or any sign of respiratory ailments like cough, sore throat, and/or has a travel history to locations reported community COVID-19 spread during the 14 days prior to the onset of symptoms. OR (2) An individual with any acute respiratory illness and/or been in contact with a confirmed or probable COVID-19 individual in the last 14 days. OR (3) An individual with severe acute respiratory illness with unexplained clinical diagnosis of alternate reasons for the problem. The central idea is to consider even a slightest probable case as a suspected patient based on above points with inconclusive or awaiting test results. While, a laboratory confirmed case is a person with a laboratory confirmation i.e. tested positive for COVID-19, irrespective of clinical signs and symptoms (asymptomatic patient). The trickiest feature of COVID-19 has lately been identified as being the asymptomatic (up to 60% in India). The risk is so heavy, spread is so fast and symptoms are of so varying nature that even travelling to a community spread country or being a physical contact of an infected person are being treated as symptoms.

5. Diagnosis of COVID-19 through biological and environmental samples {#s0025}
=====================================================================

Diagnostic testing for the SARS-CoV-2 is currently undertaken using two approaches: whole genome sequencing and real-time reverse transcriptase-polymerase chain reaction (rRT-PCR, Nucleic Acid Testing). [Table 1](#t0005){ref-type="table"} compiles the emerging diagnostics techniques being used/developed for SARS-CoV-2. The sequencing approach was used primarily in the early days of the outbreak, almost all diagnostic testing for SARS-CoV-2 is done using rRT-PCR ([@bb0635]; [@bb0640]; [@bb0270]). Many companies also launched RT-qPCR test kits to assist clinical diagnosis [@bb0090] described two 1-step RTqPCR assays to detect two different regions (ORF1b and N) of the viral genome. Saliva serves as a promising non-invasive specimen for the diagnosis of COVID-19 patients with a high positive rate of 91.7% (11/12) in determining the disease using RT-qPCR (non-probes SYBR based fluorescence signal) ([@bb0500]). Though this technique has a sensitivity of 50%--79% of detection, depending on the protocol used and the sample type; the number of clinical specimens collected ([@bb0605]), safety hazards and detection time are some issues. CT scan is suggested as an auxiliary diagnostic method to avoid reporting false results and to increase sensitivity ([@bb0270]). Early diagnosis and evaluation of disease severity of COVID-19 patients can be performed using high-resolution CT (HRCT) scan of the chest ([@bb0330]; [@bb0335]). However, inability to differentiate from other viral pneumonia makes the interpretation of the hysteresis of abnormal CT imaging tedious and inadequate ([@bb0270]). Nevertheless, the chest CT had a very low misdiagnosed rate (3.9%, 2/51) in comparison with any other method ([@bb0010]).Table 1Emerging diagnostics technological platform with their corresponding sample types and working principles for SARS-CoV-2.Table 1PlatformType of technologySample typeWorkingCRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)[a](#tf0005){ref-type="table-fn"}Nucleic acidSerumPCR, CRISPR/Ca9-mediated lateral flow nucleic assay.RAT (Rapid Antigen Test)[b](#tf0010){ref-type="table-fn"}ProteinSerumGold-coated antibodies produce colorimetric signal on paper in presence of target.RPA (Recombinase Polymerase Amplification)[c](#tf0015){ref-type="table-fn"}Nucleic acidFecal and Nasal swabsForward and reverse primers blind to DNA and amplify strands at 37 °C.RCA (Rolling Circle Amplification)[d](#tf0020){ref-type="table-fn"}Nucleic acidSerumDNA polymerase used to extend a circular primer and repeatedly replicate the sequence.SIMOA (Single-Molecule Enzyme-Linked Immunosorbent Assay)[e](#tf0025){ref-type="table-fn"}ProteinSerumDigital readout of colored product by enzymatic reaction in presence of target.NASBA (Nucleic Acid Sequence Based Amplification)[f](#tf0030){ref-type="table-fn"}Nucleic acidNasal swabsTranscription based amplification for RNA targets.LAMP (Loop-Mediated Isothermal Amplification)[g](#tf0035){ref-type="table-fn"}Nucleic acidThroat swabsIsothermal DNA synthesis using self-recurring strand displacement reactions.RT-LAMP (Reverse Transcription Loop-Mediated Isothermal Amplification)[h](#tf0040){ref-type="table-fn"}Nucleic acidNasopharyngeal aspiratesReverse transcriptase LAMP reaction for RNA targets.ELISA (Enzyme-Linked Immunosorbent Assay)[i](#tf0045){ref-type="table-fn"}ProteinSerumEnzymatic reaction to produce colored product by enzymatic reaction in presence of target.[^1][^2][^3][^4][^5][^6][^7][^8][^9]

In previous studies on SARS or MERS, lung parenchymal irregularity was reported in the central and bilateral upper lobes of lungs ([@bb0110]; [@bb0350]). However, [@bb0265] showed that the peripheral (sub-pleural), and middle and lower zones of lungs showed an abnormality at the initial stages, followed by affecting the upper lobes, and in severe cases, all five lobes of both lungs were affected. Recently, the Center for disease control and prevention ([@bb0065]) is working on Serologic (Antibody) immunoassays (IAs) testing i.e. Protein testing, for diagnosis of COVID-19 ([@bb0530]). The automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA) are most notable IAs, these detects the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in person in response to SARS-CoV-2 infection. Here the body is looked for antibodies; the positive test shows that the body has antibodies that may have resulted from infection with SARS-CoV-2 or related coronavirus. These serologic diagnostic tests are still in the research stage of development. A report by Biomedomics showed that Abbott ID Now™ COVID-19 test that utilizes isothermal nucleic acid amplification technology to detect viral RNA can detect SARS-CoV-2 in 5 min ([@bb0260]). It can take throat, nasal, nasopharyngeal, and oropharyngeal swabs as samples to run a molecular test for the RdRp gene ([@bb0530]). Further, wastewater based epidemiological (WBE) surveillance for the genetic material of SARS-CoV-19 has drawn loads of attention that can be helpful in early detection as well as resurgence of COVID-19 ([@bb0225]; [@bb0230]; [@bb0235]; [@bb0240]; [@bb0245]; [@bb0205]). WBE surveillance are expected to become handy for the potential eradication of the virus in a community.

6. Entry, replication and pathogenesis of COVID-19 {#s0030}
==================================================

SARS-CoV-2 moves from the back of the throat to the lungs and then ultimately into the blood. All coronaviruses contain specific genes in downstream regions of ORF1 that encode proteins for viral replication, nucleocapsid, and spikes formation ([@bb0520]). SARS-CoV-2 and SARS-CoV binds with a receptor called angiotensin-converting enzyme 2 (ACE-2) found on the respiratory cells with the help of S protein, which helps in entry and replication for further spreading the infection. The receptor-binding domain (RBD) is loosely attached among viruses leading to infection of multiple host ([@bb0380]; [@bb0360]). [Fig. 4](#f0020){ref-type="fig"}(a) demonstrates the interaction of viral S protein with ACE-2 on the host cell surface which is highly significant being an initiation step of infection/pathogenicity. Cryogenic Electronic Microscopic structure analysis revealed that the binding affinity of S protein to ACE-2 is about 10--20 times higher for SARS-CoV-2 than that of SARS-CoV, which is the reason for the higher transmissibility and contagiousness of SARS-CoV-2 as compared to SARS-CoV. After continuous multiplication, when virus reaches the lungs it causes inflammation in the alveoli or lung sacs leading to pneumonia. Lung inflammation makes breathing difficult for an infected person within 8 to 15 days from the onset of the symptoms and the state named acute respiratory distress syndrome (ARDS). While the functional receptor of MERS-CoV is known as Dipeptidyl peptidase 4 (DPP-4) or CD 26 ([@bb0270]). Further, the S protein invasion process is facilitated by serine protease (TMPRSS211) produced by the host cell. After entering into the host body cell a single-stranded positive RNA is released by the viral genome which translates into viral polyproteins by the translation machinery of host cell protein. These polyproteins are further sliced into effector proteins by viral proteinases 3CLpro and PLpro which results into the immune suppression. Naturally, when the virus enters the cells, it offers antigen to the antigen presentation cells (APC), a central part of the antiviral immunity in the human body ([@bb0270]), however, there still exists a lack of information about the antigen presentation of SARS-CoV-2. Therefore, till date, no SARS-CoV-2 specific antiviral agents could be discovered for a possible treatment to save lives and to produce an effective vaccine for future prevention.Fig. 4Schematic diagram of COVID-19 progression; (a) Interaction between spike (S) protein and receptor (ACE2), the encircled zone is the initiation point from where infection spreads in host \[Modified from\_ [@bb0285]; [@bb0290]\]; (b) Schematic representation of progression of SARS-CoV-2 inside host body \[Modified from [@bb0445] (Cell Death & Differentiation)\].Fig. 4

[Fig. 4](#f0020){ref-type="fig"}(b) demonstrates the progression of SARS-CoV-2 inside the host body. Inflammatory response of ARDS is mainly caused by the release of large amounts of pro-inflammatory cytokines known as 'cytokine storm' ([@bb0270]). SARS-CoV-2 infection undergoes 'cytokine storm' that triggers viral sepsis and inflammatory-induced lung injury leading to complications like pneumonitis, respiratory failure, ARDS, shock, organ failure, and potentially death ([@bb0610]; [@bb0370]). During the cytokine storm mechanism in the body a wide variety of cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α, TGFβ, and others) and chemokines (CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10, and others) are released ([@bb0190]; [@bb0050]). Although, the detailed beneficial role of cytokines is unclear currently due to the recent progression of the disease, there are already clinically tested drugs available which may add value to the current treatment process of cytokine storm. Interleukin-6 inhibitors, or IL-6 inhibitors drugs, which were found to be helpful in patients of France, China, and New York works based on blocking a specific cytokine associated with inflammation. Further, Supplementary Table 2 shows various supporting statements given by doctors and researchers regarding 'cytokine storm' mechanisms and response in our body. Overall, understanding of immuno-pathological mechanism of SARS-CoV-2 infection has great potential to develop therapeutic strategies to contain the pandemic.

7. Prognosis: susceptibility and recovery {#s0035}
=========================================

The prognosis of COVID-19 can be done by its effects on various body organs. The recovery rate from the infection of COVID-19 is varying based on its severity. People with mild condition (with few or no symptoms having a resemblance to some upper respiratory diseases such as common cold) are recovering within two weeks, the recovery duration can go up to six weeks for severe or critical disease cases. Two to eight weeks of duration from the symptoms onset has been observed to death ([@bb0395]). Various complications and health issues associated with COVID-19 have been reported, like Pneumonia affecting lungs, ARDS which may lead to respiratory and multi-organ failure ([@bb0055]; [@bb0185]), abnormal clotting, sepsis and damage to kidney, liver, and heart ([@bb0635]; [@bb0640]; [@bb0600]). In order to understand the severity of the virus outbreak, it is crucial to focus on the population groups which are at high risk, which will allow them to direct the resources towards the most vulnerable.

[Fig. 5](#f0025){ref-type="fig"}(a) summarises the case fatality rate (CFR) by the age group of various countries ([@bb0005]; [@bb0095]; [@bb0125]; [@bb0495]; [@bb0130]; [@bb0470]). CFR can be defined as the ratio of the number of confirmed deaths and the number of confirmed cases. CFR may not represent the accurate results for the deaths caused by COVID-19, as it depends on several factors such as the outbreak stage of the country, extent of testing and even accuracy of testing. The CFR shows high variance among the age groups. The age group of \>80 years is considered a vulnerable age group due to highest death risk associated with it in all the countries. However, the age group below 50 years, and children can have mild symptoms, but the risk of death is low. The CFR caused by COVID-19 is distinctive than the other historical pandemics like malaria and Spanish flu, where the most vulnerable age group was children or young adults. However, in the case of COVID-19, along with the age group the underlying health conditions also have a significant impact on the death risk ([Fig. 5](#f0025){ref-type="fig"}(b)). The early-stage CFR data of China shows that people with underlying health conditions such as cardiovascular disease, cancer, hypertension, chronic respiratory disease, and diabetes, are at higher risk ([@bb0585]). The CFR due to COVID-19 was highest for those underlying cardiovascular disease (10.5%), followed by diabetes (7.3%), chronic respiratory disease (6.3%), hypertension (6.0%), and cancer (5.6%). A comparison suggests that people with no previous underlying health condition had ten times lesser CFR (0.9%) and thus the elderly age group with pre-existing health conditions are more. Overall, the susceptibility and recovery of the disease is highly dependent upon the innate immunity of the person.Fig. 5a) Radial diagram illustrating the age correlation with morbidity and b) Pie diagram illustrating Case Fatality Rate (CFR) by age and underling health conditions due to COVID-19. \[CFR is based on [@bb0005]; [@bb0095]; [@bb0125]; [@bb0495]; [@bb0130]; [@bb0470]\].Fig. 5

8. Transmission pathway and environmental factors {#s0040}
=================================================

[Fig. 6](#f0030){ref-type="fig"} presents a transmission pathway of the COVID-19 and their intersections with various environment. The primary mode of transmission of SARS-CoV-2 is between human-to-human via respiratory droplets and contact routes. There are two modes of transmission - (1) Droplet transmission and (2) Airborne transmission. Unlike other respiratory diseases, the mode of transmission is through droplets coming out during coughing and sneezing. As per [@bb0575], the respiratory infection transmission depends on the size of drop particles. If the particle size is \>5--10 μm, it is referred to as respiratory droplets, and \<5 μm is called droplet nuclei. Also, droplet-based transmission will occur when the uninfected person is within the 1 m radius of an infected person ([@bb0145]; [@bb0480]) as the droplets can also travel within the range of 6 ft ([@bb0060]). While airborne transmission occurs when the microbe is present inside the droplet nuclei (particle size \<5 μm) and subjected to the condition that the droplet nuclei can remain in the air for a longer duration and can travel up to a distance of 1 m ([@bb0575]). However, the probability of airborne transmission of COVID-19 is very less and case-specific such as generation of aerosols like endotracheal intubation, bronchoscopy, open suctioning, administration of nebulized treatment, and manual ventilation before intubation, turning the patient to the prone position, disconnecting the patient from the ventilator, non-invasive positive-pressure ventilation, tracheostomy, and cardiopulmonary resuscitation during medical procedures and treatment process.Fig. 6Transmission pathways of the COVID-19 and their intersections with various environment.Fig. 6

[@bb0630] investigated the presence of SARS-CoV-2 in the feces of an infected person to understand if the SARS-CoV-2 can lead to any kind of gastrointestinal infections and further transmission. However, to date, no such study has been conducted that could establish a relationship between the fecal−oral transmission of the SARS-CoV-2. [@bb0640] reported that viral shedding is one of the most significant ways of transmission and observed that the viral shedding was found to last for 37 days in survivors. The amount of viral load contributed to the environment by asymptomatic and symptomatic patients was conducted by [@bb0030], [@bb0635] and [@bb0645]. The authors reported that transmission was possible even in the case of asymptomatic patients, but in the case of symptomatic patients increase in viral loads was observed.

As of now, the environmental factors that has been studied to understand the COVID-19 transmissions, are the ambient environmental temperature, humidity but still, no authenticity on the relationship is confirmed yet ([@bb0545]; [@bb0550]; [@bb0555]; [@bb0560]; [@bb0235]; [@bb0505]). Apart from climatic conditions (temperature and humidity), the transmission may be further triggered by population and medical facility ([@bb0105]; [@bb0180]). Based on the assumption that the SARS-CoV-2 is similar to SARS-CoV, it has been hypothesized that the SARS-CoV-2 may not survive at high temperature and humidity ([@bb0070]; [@bb0235]; [@bb0240]; [@bb0245]; [@bb0505]) due to breakdown of the lipid membrane at elevated temperature ([@bb0435]). [@bb0040] investigated the effect of temperature and humidity on the transmission of COVID-19 disease. For the study, the data until March 22, 2020, were analyzed for sub-tropical countries. It was found that from January 22, 2020, to March 21, 2020, the number of cases increased in the region with a mean temperature range of 4--17 °C and absolute humidity 3-9 g/cm^3^. However, for temperature and absolute humidity higher than 17 °C and 9 g/cm^3^ lesser number of cases were reported. For countries with temperatures higher than 18 °C (between March 11 and 19, 2020) like India, Brazil, Indonesia, and Pakistan, the sudden rise in COVID-19 cases may be due to the recent initiation of large-scale COVID-19 testing. Based on the data obtained, it was hypothesized that the lower number of cases in a tropical climate might be due to the warm, and humid climate. The underlying hypothesis of decrease in the spread of viruses during warmer seasons is higher vitamin D levels, resulting in better immune responses ([@bb0020]; [@bb0235]; [@bb0240]; [@bb0245]). Interestingly, a common man notion is that in cold weather, people tend to stay inside, often in a closed room, at times close to each other, and that enhances the infection probability. A study confirmed a strong relationship does exist between the reported cases, temperature, and absolute humidity, but the basis of this relationship is not lucid. It is difficult to delineate the effect of environmental factors like temperature and humidity, individually and in combination.

[@bb0525] studied the behavior of SARS-CoV-1 and SARS-CoV-2 and observed that SARS-CoV-1 and CoV-2 are very similar in terms of stability in the environment and reported that SARS-CoV-2 remained active on the surface of the plastic and stainless steel - 48--72 h; cardboard - 24 h; copper -4 h; 3 h in aerosols under experimental laboratory conditions but in real situation, this retention time may vary depending on temperature, humidity, ventilation, and the extent of virus deposited on any surface ([@bb0235]; [@bb0505]). [@bb0545], [@bb0550], [@bb0555] and [@bb0560] estimated an effective reproductive number (R) to understand the severity of infection ([@bb0535]). The R was developed based on the data obtained from 100 Chinese cities with \>40 cases. The study was carried out to understand the effect of climatic factors (temperature and humidity) on R, which will indirectly can tell about the transmission of SARS-CoV-2. The results showed lowering of R value by 0.0225 and 0.0158 with increase in temperature by 1 °C and increase in relative humidity by 1%, respectively. The finding reported by [@bb0545], [@bb0550], [@bb0555] and [@bb0560] are consistent with the findings for the influenza virus ([@bb0340]; [@bb0460]; [@bb0275]; [@bb0440]), where the high temperature and high humidity leads to a significant reduction in transmission of the influenza virus. This might be due to the following reasons: (i) Cold and dry weather might cause weakness in the immunity of the host ([@bb0220]; [@bb0120]), (ii) unlike influenza virus they might be more stable in lower temperature and within the respiratory droplets ([@bb0300]; [@bb0475]). Also, the observations made for SARS CoV for temperature and humidity ([@bb0070]; [@bb0625]) were inconsistent with the findings of [@bb0545], [@bb0550], [@bb0555] and [@bb0560].

9. Current treatment options for COVID-19 {#s0045}
=========================================

[@bb0270] reported at present, there is no proven antiviral agent that can control the COVID-19 outbreak and inactivate SARS-CoV-2. By 29th April 2020, no drug has been approved by [@bb0515] that can prevent COVID-19. Currently, management strategies for COVID-19 patients with mild symptoms include infection prevention by using oseltamivir/ intravenous antibiotics, clinical supportive measures for severe patients such as oxygen and mechanical ventilator support ([@bb0280]). Some of the therapeutics drugs and therapy which are under investigation for controlling COVID-19 are: (i) *Ivermectin with Vero-hSLAM cells*; (ii) *Nafamostat*; (iii) *Remdesivir*; (iv) *Hydroxychloroquine and Chloroquine*; and (v) *Convalescent plasma therapy*.

FDA-approved *Ivermectin* as an anti-parasitic and anti-viral in-vitro activity. *Ivermectin* inhibits IN nuclear import and the human immunodeficiency virus-1 (HIV-1) replication and thus reduces infection by \~5000 times within two days after consumption. It showed a 99.98% reduction in viral RNA ([@bb0045]). Another drug, *Nafamostat mesylate* (Fusan) as demonstrated by Japanese researchers can inhibit the fusion of SARS-CoV-2 (S) protein and initiated membrane at achievable and safe concentrations in the patients ([@bb0175]). *Remdesivir* is an antiviral drug that is intravenous and inhibits the synthesis of viral RNA by preventing the replication of RNA by early termination of RNA transcription ([@bb0270]). [@bb0295] successfully demonstrated that Remdesivir is a potent antiviral towards SARS and MERS-CoV. As per the CDC, "Remdesivir has *in-vitro* activity against SARS-CoV-2 and *in-vitro* and *in-vivo* activity against related beta coronaviruses".

Hydroxychloroquine and chloroquine are anti-malarial drugs that are taken through oral administration, and both of the drugs belong to the quinolone family. [@bb0620] demonstrated that both the medicines have a potent antiviral property that can control SARS-CoV-2 in-vitro. [@bb0415] reported that the use of hydroxychloroquine is much safer and has more potential of inhibiting SARS-CoV-2. Hydroxychloroquine has been proven more successful than chloroquine (inhibition rate did not exceed 50%) at inhibiting SARS-CoV-2 ([@bb0615]). [@bb0345] and [@bb0325] reported negative results of hydroxychloroquine and chloroquine during random testing for influenza in random patients. Henceforth, there is lack of report, facts and figures to support the use of hydroxychloroquine and chloroquine as an efficient treatment mechanism ([@bb0620]).

Early signs are that convalescent plasma therapy can reduce the mortality rate in SARS-CoV-2 patients ([@bb0085]; [@bb0250]; [@bb0455]). [@bb0310] showed recovery from SARS-CoV-2 at early-stage of treatment with convalesced plasma therapy. Unlike SARS-CoV ([@bb0310]) and MERS-CoV ([@bb0215]; [@bb0270]), many patients are donating plasma with SARS-CoV-2 antibodies to control COVID-19. [@bb0115] demonstrated the potential of convalescent plasma therapy to treat the severe COVID-19 patients. 10 patients were treated with plasma therapy, a 200 ml of convalescent plasma neutralize with antibody titers above 1:640 was given to the patients who showed rapid improvement in symptoms with three days of convalescent plasma transfusion. However, treatment by convalescent plasma therapy is still questionable ([@bb0280]).

10. Conclusions {#s0050}
===============

COVID-19 is a severe global health issue which is caused by SARS-CoV-2. The genomic study revealed that the phylogeny of the SARS-CoV-2 is very similar to SARS-like bat/Pangolin. The disease result in respiratory illness like SARS-CoV and MERS-CoV and may cause death in severe cases. The mortality is significantly higher in the elderly age group, mostly having pre-existing health conditions. At the initial stage the disease may be identified by symptoms such as fever, dry cough, muscle pain and fatigue but challenge of identifying the asymptomatic patient is huge. The transmission is mainly through the respiratory droplets and their diameters, and through direct contact with an infected surface. In the case of airborne transmission, the probability of being infected is very less and case-specific. The higher transmissibility and contagiousness of SARS-CoV-2 may be attributed to the high binding affinity of SARS-CoV-2, S protein to ACE2. The rapid transmission is due to the weak linkage between the receptor-binding domain (RBD) of SARS-CoV2 and the host cell. Some of the profound drugs available to control cytokine storm are Interleukin-6 inhibitors or IL-6 inhibitors, but for older people or people with past medical histories inhibiting the immune system may result in severe health issues. One of the probable ways to curb the infection is to restrict the binding between S protein of SARS-CoV-2 to ACE2. Though the cause and effects are known still the transmission mechanism is not fully understood.

As a control measure, what best can be done and being implemented globally are self-isolation and social distancing. Once there is established virus transmission within the community, proper quarantine of symptomatic may have a meaningful impact to control further spread. Also, more clinical testing apart from laboratory testing should be carried out to validate the proposed drugs and therapy further. Strong ways to hold the COVID-19 outspread are: i) better surveillance plans like wastewater based epidemiological surveillance; ii) local and regional support through government and community collaboration; iii) cooperation to health workers for more clinical testing; iv) awareness through the improvement of health advisories; v) encouragement of clinical testing of the cases with mild symptoms; and vi) better resource allocations to the economic vulnerable groups during the social distancing. Last but not the least, research is the key to bring the breakthrough to contain the COVID-19 spread for which some of the key research aspects may be: i) Development of statistical-based predictive model to understand the future outbreak or re-occurrences of COVID-19 or alike pandemic; ii) Understanding the environmental impacts to curb the COVID-19 through additional ways of adaptation to the local conditions; iii) Development of comprehensive library for SARS-COV-2; iv) Invention of drug and therapy to control the contagion by various scientific communities; v) Pace the global testing of patient to obtain the data to find the troubleshooting of asymptomatic patient identification; vi) Lifestyle enhancement to increase the immunity, and sanitation awareness; vi) Identification of the hotspot areas to target better containment strategies; and vii) Distribution of immunity boosting medication to narrow down risk and vulnerability of the population as a precautionary measure.
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